Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
about
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligandViral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-AntagonistsRecent vaccine development for human metapneumovirusInhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in MiceA live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein.Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzeesA respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.Requirement of cysteines and length of the human respiratory syncytial virus M2-1 protein for protein function and virus viabilityGranulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroadsInfection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidatesIntranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.Progress in the development of human parainfluenza virus vaccinesNew insights for development of a safe and protective RSV vaccineRational design of human metapneumovirus live attenuated vaccine candidates by inhibiting viral mRNA cap methyltransferaseViral etiology of severe pneumonia among Kenyan infants and children.Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneRecombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positionsCurrent concepts and progress in RSV vaccine development.Influence of maternal antibodies on neonatal immunization against respiratory viruses.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Immunization strategies for the prevention of pneumovirus infections.Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates.Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsAn evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in childrenRole of respiratory syncytial virus in acute otitis media: implications for vaccine developmentMammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractHuman metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children.Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials
P2860
Q24683245-AADB5AFB-0A65-4B82-A28F-5FDE884C1421Q26745547-A4A1F4B6-965A-4F44-8A79-C247F3579F2BQ27023742-F958D16B-1E36-423E-B8E2-3A4CA6E21AE7Q27490424-72F337D6-3332-4E01-BA0E-B12F66ECAE55Q30377443-7E1904FD-514B-4F9E-A30A-9DEC80D2BF32Q30378263-5932C8A7-03AB-40C5-A550-7C0414D24C54Q30440686-BF7AE47D-697D-4463-B1CC-AA373DE4B414Q33605207-52D5E466-60D5-48F4-B699-237B5696A147Q33690612-84FF7F76-F509-43C2-AA2B-706DA4351D4BQ33712986-64A7DBEF-622C-4690-B5A7-6C1E4713E988Q33776507-CB0DD530-230D-4751-9692-5F265DA8A97FQ33826900-68F50F81-43D1-41AD-8E26-85AA4110F19BQ33840469-ED88DA3C-11D9-44CF-AED2-3AA138C88A05Q33848343-2C9B4ACB-C237-4A82-B6C3-B3954F9D4BDFQ33849224-63AD0077-C156-44D7-A6B5-E074798E0DFCQ33849620-ADAE3E44-0FE3-47C7-8DAE-0B5C5265A0FBQ33870105-891BBAB7-DAA4-44F9-A3A2-F553504A52A1Q33916408-CFA345FD-0A87-4B3B-A563-650B67E9C7DBQ33984333-F8247B75-0860-43A7-BDBB-E04B2CC9E27EQ34033869-8A80A7C4-F629-48B2-957F-EC23E4469DB6Q34151865-865B8DEE-84EB-424A-9E5D-B108DE4D03B2Q34209872-F48B4315-08E8-45E7-BE03-9A5A71AA439CQ34249859-35132C97-EBC6-4201-8CEE-8C7B5CFF2BF6Q34261898-ADF6FD0B-71E9-41ED-925B-F7E627CBC2FFQ34262582-0BAC52E3-B0BA-42FA-9BB7-24E5A78CDBC6Q34328895-D118BEF0-26E3-4B32-B2C0-A5DA258E49A3Q34359826-FF43A5FE-3E8D-4FD9-90B8-1212C2033D52Q34396689-58543147-721B-4E54-91FB-34F58847EFD3Q34398563-A02CA671-BB56-4A91-9ECD-6DBB37B9A4E4Q34504791-C4766DA6-965C-4782-8933-199BD1836838Q34615678-1CE06315-E861-46CE-8769-5F6FD27C4F16Q34651319-D14F564A-9369-498E-A7CC-4B69480C3E89Q34717853-AFD1169C-7065-40D3-BB40-5D3A74B99821Q34990420-34CA16D3-7742-4BED-B17A-1A8B50B661F5Q35566601-5083EBEE-A27C-43B1-9B55-38BA37E119A2Q35595950-B472CCF4-26FF-4F5C-AFC6-262E78008196Q35689593-6B978867-2816-4913-8B80-04A73D3DA054Q35690781-19A84775-A120-430A-AF45-88E7B85A3628Q35697523-9A3AC0E3-F4A5-44EC-8F2A-C6B9809CE47EQ35761061-29B7DE87-E6E7-4904-8961-85B973EA52AC
P2860
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Evaluation of a live, cold-pas ...... vaccine candidate in infancy.
@en
type
label
Evaluation of a live, cold-pas ...... vaccine candidate in infancy.
@en
prefLabel
Evaluation of a live, cold-pas ...... vaccine candidate in infancy.
@en
P2093
P356
P1476
Evaluation of a live, cold-pas ...... vaccine candidate in infancy.
@en
P2093
Anderson EL
Chanock RM
Eichelberger M
Halburnt LL
Randolph VB
P304
P356
10.1086/315859
P407
P577
2000-09-22T00:00:00Z